From Jeff Wolf, MD & Tom Martin, MD: Grand MMTI
UCSF Stephen & Nancy Grand Multiple Myeloma Translational Initiative - Speeding Development of Improved Multiple Myeloma Therapies For Our Patients
Through the compassionate support of our donors, the UCSF Stephen & Nancy Grand Multiple Myeloma Translational Initiative (Grand MMTI) is pioneering groundbreaking treatments and leading world-changing medical research in the areas of cellular therapy and novel treatment paradigms.
Help us translate that research into lifesaving care for our patients.
Join us and donate today and help us reach our goal of raising $2,500,000 by December 31 to fund the clinical development of cancer immunotherapies, known as CAR T-cell therapies, for patients with multiple myeloma and other blood cancers. Early clinical studies have demonstrated promising results, particularly in patients for whom other therapies have been unsuccessful. Your support will help us work toward executing a clinical trial to further test the safety and efficacy of CAR T-cell therapy.
Your gift – and every gift to the Grand MMTI – makes a difference. It has the power to become the tipping point, when research discoveries are transformed into lifesaving care. On behalf of every patient and family member who battles this disease, thank you. Together, we are bringing new hope to cancer patients here and around the world.
Please contact Sydney Pietrzak, assistant director of development, to make your gift over the phone or with questions at Sydney.Pietrzak@ucsf.edu or (415) 502-1197.
Who We Are
The Stephen and Nancy Grand Multiple Myeloma Translational Initiative (Grand MMTI), launched in 2009 and led by Jeff Wolf, MD and Tom Martin MD, is the premier myeloma translational program on the West Coast, with the goal of speeding development of improved multiple myeloma treatments. Nina Shah, MD and Sandy Wong, MD joined the clinical care team in 2016.
We are the largest multiple myeloma clinical practice and research program on the West Coast. Utilizing the six pillars of our program, the Grand MMTI works to improve care for myeloma patients and speed development of improved myeloma therapies. Our program, with its internationally recognized cancer researchers and world-class myeloma clinicians, has the resources and expertise to tackle the complex issues associated with myeloma disease biology and use that knowledge to develop novel treatment approaches.
Grand MMTI physician-scientists are learning how to manipulate and harness a patient’s immune system to seek out and destroy cancer cells. The Grand MMTI is one of the few programs nationwide with the clinical trials expertise and capabilities to administer novel and promising multiple myeloma cellular immunotherapies to our patients. Please click here to watch Grand MMTI leader Tom Martin, MD discuss CAR T-cell therapy, one type of immunotherapy offering new hope to relapsed/refractory patients. Arun Wiita, MD, PhD is one of the scientists collaborating with the Grand MMTI is working hard to improve upon what has already been accomplished with these therapies.
Grand MMTI Program Pillars
- Basic Science Research - world renowned labs working on key projects addressing different aspects of multiple myeloma biology, treatment and patient stratification
- Clinical Research (trials) - specialists in first-in-human clinical trials with the expertise and facilities to support complex trials including cell-based therapies
- Translational Laboratory - evaluating novel therapies using cutting-edge technologies and multiple myeloma models
- Tissue Bank and Annotated Database - our extensive tissue bank contains samples representing all stages of disease progression allowing for in-depth analysis comparing experimental data to patient responses
- Industry Collaborations - working with industry is key in getting novel therapies to patients. We provide our industry partners with relevant models, data, scientific expertise and access to clinical key opinion leaders to drive therapeutic development
- Scientific Advisory Board - The Grand MMTI's Scientific Advisory Board (SAB) consists of internationally recognized myeloma clinicians and researchers, who provide scientific and strategic guidance on the Grand MMTI clinical and research programs.
Grand MMTI Facts & Figures
- Has grown over 20 fold in the last 10 years from 75 patients to over 1,500 patients annually
- Manages our patients as one integrated program from diagnosis through transplant, relapse and beyond
- Is a long-standing member of the Multiple Myeloma Research Consortium (MMRC)
- Has 4 full-time and 3 part-time myeloma clinicians
- Has 14 associated basic science laboratories
- Has had novel drugs out-licensed to start-up companies from 2 Grand MMTI associated labs
- Has had over 15 industry partnerships in the last 6 years
- Is among the top translational programs in the UCSF Helen Diller Family Comprehensive Cancer Center
Resources and Capabilities
- Comprehensive clinical trials and clinical translational program
- Multiple myeloma tissue bank and annotated database
- Robust phase 1 capabilities
- Expertise in cell-based and immune-based therapies
- Expanding amyloidosis practice
- Extensive resources to support correlative science
From left: Tom Martin, MD, Cammie Edwards, PhD, Sandy Wong, MD, Nina Shah, MD, and Jeff Wolf, MD
Arun Wiita, PhD